Core Findings - A study published in Nature Medicine indicates that taking Centrum Silver daily may slow biological aging markers in older adults [1] - The research is based on the COSMOS trial, which is the first large-scale randomized controlled trial examining the effects of daily multivitamins on biological aging [1][2] - The study found that participants taking Centrum Silver experienced a statistically significant slowing in all five epigenetic clocks, equating to approximately four months less biological aging over two years compared to the placebo group [1][2] Study Details - The COSMOS trial involved nearly 1,000 older adults, with participants randomized to receive either a daily multivitamin, cocoa extract, both, or a placebo [1] - The study specifically measured biological aging through five DNA-based epigenetic clocks, which assess changes in DNA that occur naturally with aging [1] - Results showed that individuals with accelerated biological aging at baseline benefited more from the multivitamin intervention [1][2] Implications for Centrum - The findings support the notion that Centrum Silver is a safe, accessible, and low-cost intervention that may contribute to healthy aging [1] - Centrum has a long-standing commitment to nutritional research, being the most clinically studied multivitamin brand globally [1] - The study reinforces the credibility and scientific rigor of Centrum's product offerings, particularly in relation to aging and overall health [1]

In the 20th century, we began to die slowly—from our own biology, rather than plagues or predators. Fast deaths are now the exception, not the rule. Today, some 45 million deaths a year owe to biological aging, and we treat these deaths as mostly inevitable. But what if they are not? What if preventing our newly slow deaths is a moral and economic imperative? Drawing on interviews with 102 scientists and original economic modeling, Dr. Romanni-Klein reveals why advancing progress in the young science of agi ...

Core Viewpoint - BioVie Inc. is advancing its clinical-stage drug candidate bezisterim, which shows promise in treating neurological disorders, particularly Alzheimer's disease, Parkinson's disease, and long COVID, by modulating inflammation and potentially altering biological aging [1][9]. Group 1: Bezisterim's Mechanism and Effects - Bezisterim differs from traditional Alzheimer's treatments by modulating inflammation and affecting multiple genes simultaneously, potentially altering biological age through anti-inflammatory epigenetic modifications [2][3]. - In a Phase 3 study, bezisterim demonstrated significant effects on biological aging, with bezisterim-treated patients showing an average biological age reduction of -3.16 years for SBCAge and -4.12 years for PhenoAge compared to placebo [5]. - Bezisterim has shown improvements in metabolic and inflammatory biomarkers, including a decrease of -8.5 mg/dL in fasting glucose and -15 mg/dL in cholesterol levels compared to placebo [5]. Group 2: Clinical Trials and Studies - The ongoing Phase 2 SUNRISE-PD trial is evaluating bezisterim's safety and efficacy in Parkinson's disease, with topline data expected in late 2025 or early 2026 [5]. - Previous studies indicated that bezisterim improved motor control in Parkinson's patients when combined with levodopa, with no adverse events reported [6]. - The Phase 2 ADDRESS-LC study aims to assess bezisterim's efficacy in reducing neurological symptoms associated with long COVID, targeting cognitive dysfunction and fatigue [7]. Group 3: Company Overview and Future Directions - BioVie Inc. focuses on developing innovative therapies for neurological disorders and advanced liver disease, with bezisterim targeting neuroinflammation and insulin resistance, key factors in Alzheimer's and Parkinson's diseases [9]. - The company is also advancing its orphan drug candidate BIV201 for liver cirrhosis, which has received FDA Fast Track status [9].